Feasibility study of TS-1 adjuvant therapy for resected biliary tract cancer - Feasibility study of TS-1 adjuvant therapy for resected biliary tract cancer

Keio University School of Medicin0 个研究点目标入组 50 人开始时间: 2012年10月5日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1) with history of TS-1 administration 2)with interstitial pneumonia or pulmonary fibrosis within 28 days before accrual 3)with diarrhea 4)with clinically important infection 5)blood infusion within 14 days before accrual 6)sever complication(Heart failure, renal failure, liver failure, Hemorrhagic peptic ulcer, Intestinal paralysis, Ileus, uncontrollable diabetes mellitus etc) 7)more than moderate degree of Ascitic fluid and Pleural effusion 8)has active carcinoma except carcinoma in situ 9)administered flucytosine, Phenytoin, Warfarin potassium 10) pregnant women or women who like be pregnant and willing to get pregnant, men who want his partner to be pregnant 11) known sever drug allergies 12) sever mental disorder 13) doctor's decision not to be registered to this study

发起方

Keio University School of Medicin